Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010
Cash flows from operating activities:
Net loss	$ (35,906)	$ (45,974)	$ (56,326)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	2,054	2,577	2,965
(Income) loss from equity investment	645	(58)	730
Impairment of equity investment	3,602	0	0
Accretion of redeemable preferred stock of subsidiary	0	525	2,367
Asset Impairment	0	0	765
Depreciation	5,192	6,431	7,438
Amortization of bond premium and interest expense	2,018	2,490	91
Other non-cash transactions	(117)	114	314
(Increase) decrease in operating assets:
Accounts and license fee receivables	(14,066)	(4,046)	4,480
Inventories	(7,600)	(6,697)	(7,971)
Other assets	3,032	(15,586)	(785)
Increase (decrease) in operating liabilities:
Accounts payable	(1,790)	3,405	774
Accrued liabilities	(6,081)	10,761	3,762
Deferred revenue	(9,642)	37,573	6,404
Net cash used in operating activities	(58,659)	(8,485)	(34,992)
Cash flows from investing activities:
Capital expenditures	(4,453)	(3,350)	(2,481)
Convertible loan to affiliate	0	(600)	(600)
Treasury notes matured	12,000	55,000	32,500
Treasury notes purchased	0	(33,019)	(59,677)
Net cash provided by (used in) investing activities	7,547	18,031	(30,258)
Cash flows from financing activities:
Repayment of debt	(173)	(306)	(377)
Proceeds from debt	0	4,000	0
Proceeds received from noncontrolling interest in subsidiary	954	0	0
Proceeds from sale of common stock, net of registration fees	64,003	32,930	32,104
Payment of preferred dividends and return of capital	(7,624)	(15,226)	(3,695)
Common stock issued for stock plans and related expenses	0	0	(151)
Net cash provided by financing activities	57,160	21,398	27,881
Effects on cash from changes in foreign currency rates	51	4	13
Net increase (decrease) in cash and cash equivalents	6,099	30,948	(37,356)
Cash and cash equivalents-beginning of period	51,415	20,467	57,823
Cash and cash equivalents-end of period	$ 57,514	$ 51,415	$ 20,467